Abstract
Background Fluconazole-resistant Candida parapsilosis has emerged as a significant healthcare-associated pathogen with a propensity to spread patient-to-patient and cause nosocomial outbreaks, similar to Candida auris. This study investigates a prolonged outbreak of fluconazole-resistant C. parapsilosis across multiple years and healthcare centers in Germany.
Methods We employed whole-genome sequencing of isolates from the outbreak, other regions within Germany, and compared them with isolates from a global distribution to understand the molecular epidemiology of this outbreak. Additionally, we used the genomic dataset of 258 samples to identify loci with high discriminatory power to establish the first multi-locus sequence typing (MLST) strategy for C. parapsilosis.
Findings A clonal, azole-resistant strain of C. parapsilosis was observed causing invasive infections over multiple years and in multiple hospitals within the outbreak city. Including this outbreak clone, we identified three distinct ERG11 Y132F azole-resistant lineages in Germany, marking the first description of this azole-resistance in the country and its endemic status. Using the novel MLST strategy, isolates were categorized into 31 sequence types, proving the utility of the typing scheme for genetic epidemiology and outbreak investigations as a rapid alternative to whole genome sequencing.
Interpretation Temporal and genomic reconstruction of the outbreak indicated that transfer of patients between healthcare facilities was likely responsible for the persistent reimportation of the drug-resistant clone and subsequent person-to-person transmission. This research underscores the importance of monitoring of C. parapsilosis epidemiology, not only in Germany but globally. The emergence of azole-resistant lineages necessitates continuous surveillance and rigorous infection control measures. By combining large-scale genomic epidemiology and introducing a novel typing method, our study offers valuable insights into the management of emerging healthcare-associated pathogens, with direct implications for public health and clinical practice.
Funding German Federal Ministry for Education and Research, German Research Foundation, German Ministry of Health
Evidence before this study The epidemiology of candidemia has undergone dramatic changes in recent years. New pathogenic species, such as Candida auris, have emerged, and existing species like Candida parapsilosis have increased in prominence. There has also been a worrying increase in drug resistance among Candida species. Moreover, numerous drug-resistant outbreaks of C. parapsilosis have been reported worldwide and are challenging to control due to their prolonged and intermittent nature. The evidence sources considered for this study were journal articles found through the search terms “Candida parapsilosis”, “outbreak”, “azole resistance”, and/or “fluconazole” in PubMed and Google Scholar.
Added value of this study This study adds to the existing evidence by utilizing whole genome sequencing in conjunction with hospital records to analyze a prolonged outbreak of clonal, azole-resistant C. parapsilosis that occurred across multiple years and medical centers. This study demonstrates that patient transfers can result in the reimportation of outbreak clones, posting a significant challenge for infection control. We also reveal that the outbreak clone is closely related to drug-resistant isolates from other continents, highlighting the global spread of drug-resistant C. parapsilosis. Furthermore, the study addresses the need for rapid strain differentiation in outbreak settings by establishing and validating a set of four loci for sequence-based typing, which provide a highly discriminatory tool for epidemiologic investigations.
Implications of all the available evidence This study underscores the global challenge of azole-resistant C. parapsilosis and its importance as the causative agent of nosocomial outbreaks. Clinicians should be aware of the evolving epidemiology of C. parapsilosis and the prevalence of drug-resistant strains, emphasizing the importance of appropriate antifungal stewardship and infection control measures. The study emphasizes the challenges caused by inter-hospital transmission and their role in persistent outbreaks, highlighting the need for robust surveillance and coordination among healthcare facilities. Furthermore, the establishment of a sequence-based typing scheme is a valuable tool for rapid assessment of outbreak clones, which can aid in outbreak tracking and containment efforts.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was supported by The Federal Ministry for Education and Science (Bundesministerium fuer Bildung und Forschung) within the framework of InfectControl 2020 (Projects FINAR 2.0, grant 03ZZ0834). The work of the German National Reference Center for Invasive Fungal Infections is supported by the Robert Koch Institute from funds provided by the German Ministry of Health (grant 1369-240). AEB is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under its Excellence Strategy, EXC 20151, Project ID 390813860.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of the University Hospital Jena approved this study under registration number 2024-3255-Daten.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Raw FASTQ files for novel isolates sequenced in this study were uploaded to the NCBI Sequence Read Archive and are publicly available under BioProject PRJNA996760. Accession numbers for the publicly available sequence data used in this study are listed in Supplemental File 1. Genbank records for the Sanger sequencing of the MLST loci performed in this study are listed in Supplemental Table 2.
